The novel nociceptin/orphanin FQ receptor antagonist Trap‐101 alleviates experimental parkinsonism through inhibition of the nigro‐thalamic pathway: positive interaction withL‐DOPA
Copyright policy )The novel nociceptin/orphanin FQ receptor antagonist Trap‐101 alleviates experimental parkinsonism through inhibition of the nigro‐thalamic pathway: positive interaction withL‐DOPA
AbstractIn this study we investigated whether the recently discovered antagonist of the nociceptin/orphanin FQ (N/OFQ) opioid peptide (NOP) receptor, 1‐[1‐(cyclooctylmethyl)‐1,2,3,6‐tetrahydro‐5‐(hydroxymethyl)‐4‐pyridinyl]‐3‐ethyl‐1,3‐dihydro‐2H‐benzimidazol‐2‐one (Trap‐101) changed motor activity in naïve rats and mice, and alleviated parkinsonism in 6‐hydroxydopamine hemilesioned rats. In naïve rats, Trap‐101 stimulated motor activity at 10 mg/Kg and inhibited it at 30 mg/Kg. Such dual action was also observed in wild‐type but not NOP receptor knockout mice suggesting specific involvement of NOP receptors. Trap‐101 alleviated akinesia/bradykinesia and improved overall gait ability in hemiparkinsonian rats, being effective starting at 1 mg/Kg and without worsening motor deficit at 30 mg/Kg. To investigate the circuitry involved in the Trap‐101 action, behavioral tests were performed in rats undergoing microdialysis. The anti‐akinetic/anti‐bradykinetic effects of Trap‐101, given systemically (10 mg/Kg) or perfused in substantia nigra reticulata (10 μM), were associated with reduced glutamate and enhanced GABA release in substantia nigra, and reduced GABA release in ipsilateral ventro‐medial thalamus. When combined with ineffective doses ofl‐DOPA (0.1 mg/Kg), Trap‐101 evoked larger neurochemical and behavioral responses. These data show that Trap‐101 is an effective NOP receptor antagonistin vivoand confirm that NOP receptor antagonists alleviate parkinsonism through blockade of nigral NOP receptors and impairment of nigro‐thalamic transmission.
- University of Padua Italy
- University of Ferrara Italy
Mice, Knockout, Dyskinesia, Drug-Induced, Dose-Response Relationship, Drug, Microdialysis, Narcotic Antagonists, Glutamic Acid, Motor Activity, Functional Laterality, Antiparkinson Agents, Levodopa, Mice, Inbred C57BL, Disease Models, Animal, Mice, Parkinsonian Disorders, Neural Pathways, Animals, Benzimidazoles, Drug Interactions, Oxidopamine, Psychomotor Performance
Mice, Knockout, Dyskinesia, Drug-Induced, Dose-Response Relationship, Drug, Microdialysis, Narcotic Antagonists, Glutamic Acid, Motor Activity, Functional Laterality, Antiparkinson Agents, Levodopa, Mice, Inbred C57BL, Disease Models, Animal, Mice, Parkinsonian Disorders, Neural Pathways, Animals, Benzimidazoles, Drug Interactions, Oxidopamine, Psychomotor Performance
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).39 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!